title: [On filo- and ontogenetic development of dopaminergic regylation of wakefulness-sleep cycle in vertabrates].
abstract: The comparative immunohistochemical researches of dofamine containing neurons and fibers are carried uot in telencephalic and diencephalic departments of the brain in different vertebratts (adults rats, rats aged 14 and 30 days and frogs). For analysis of quantitative changes dynamics in thyrozinhydroxylase, D1 and D2 immunoreactive material in sleep-wakefulness cycle the model of sleepdeprivation is used. There are found the facts of morphofunctional correlations in the reactions of dophaminergic system during ontogeny and phylogeny. Besides, the pharmacological effects of dofamine agonist and antagonists on the sleep-wakefulness cycle in young rats and in frogs are shown. So, dopamine and its agonist apomorphine increase in sleep-wakefulness cycle duration of sleep-like state ofcataplexy (homolog of the sleep) in frogs, in 30-day-old rats it increase the share of wakefulness and catalepsy. D1 receptors antagonist (SCH 23390) adminisrated to frogs, caused increase of wakefulness and catatonic type states duration, where as D2 receptors antagonist (apomorphine) increased cataleptic condition. Administration of dopamine antagonist (haloperidol) to 30-day-old rats previously causes the increase of cataleptic state, after which the slow wave sleep state is enhanced. The questions of phylo-, ontogenetic formation of dopaminergic system regulating role in sleep-wakefulness cycle, when transition mainly from neurosecretory diencephalic influences of dophamine to the mainly neurotransmittory functins of telencephalic regions occured, is discussed.
authors: G A
authors: GA
authors: Oganesian
authors: E A
authors: EA
authors: Aristakesian
authors: I V
authors: IV
authors: Romanova
authors: S I
authors: SI
authors: Vataev
authors: V V
authors: VV
authors: Kuzik
mesh_terms: D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D001931:Brain Mapping; D002375:Catalepsy / Q000139:chemically induced / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism / Q000502:physiology; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000502:physiology; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D011896:Rana temporaria / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000378:metabolism / Q000502:physiology; D012890:Sleep / Q000187:drug effects / Q000502:physiology*; D014714:Vertebrates / Q000254:growth & development / Q000502:physiology; D014851:Wakefulness / Q000187:drug effects / Q000502:physiology*
chemical_list: D001552:Benzazepines; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; C534628:SCH 23390; D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine